Related Experiment Video
Updated: Jun 18, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Diabetic medications in pregnancy.
1University Hospital Birmingham, Queen Elizabeth Hospital, Department of Endocrinology, Edgbaston, Birmingham B15 2th, UK. jamesywyoung@yahoo.co.uk
Current Diabetes Reviews
|November 21, 2009
Summary
The use of oral antidiabetic agents (OADs) during pregnancy is increasing due to rising diabetes and obesity rates. This review examines the safety evidence for OADs in pregnant women, considering new incretin-based therapies.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Increasing prevalence of diabetes and obesity globally.
- Rising number of women with diabetes conceiving.
- Introduction of novel oral antidiabetic agents (OADs), including DPP-IV inhibitors and GLP-1R analogues.
Purpose of the Study:
- To review the current evidence on the safety of oral antidiabetic agents (OADs) during pregnancy.
- To discuss the evolving guidelines regarding OAD use in pregnant women.
- To address concerns surrounding incretin-based therapies in gestational diabetes.
Main Methods:
- Comprehensive literature review of existing studies and clinical guidelines.
- Analysis of safety data for traditional and novel OADs in pregnancy.
- Evaluation of recommendations from health authorities like NICE.
Main Results:
- Historically, insulin and diet were primary treatments for gestational hyperglycemia.
- Recent guidelines suggest a potential role for OADs in managing diabetes during pregnancy.
- Evidence on the safety of newer agents like DPP-IV inhibitors and GLP-1R analogues is still developing.
Conclusions:
- The safety of OADs in pregnancy remains a critical concern.
- Further research is needed to establish definitive safety profiles for all OADs.
- Individualized treatment decisions are necessary, balancing maternal hyperglycemia control with fetal safety.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...